Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis

This dataset was the minimal dataset of the research article entitle 'Safety of ChAdOx1 nCoV-19 vaccination in patients  with end-stage renal disease on hemodialysis'.  The study aims to investigate the localized and systemic adverse effects (AEs) within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-AstraZeneca) vaccination in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). The first dataset is the raw data for logistic regression analyses examining the risk factors in association with AEs, another dataset  contains the second- and the seventh- day incidences of various AEs depicted in bar graphs. It comprises variables recording the status of patient-reported local and systemic AEs in questionnaire on the second and seventh days after vaccination as well as patients' baseline demographic and clinical characteristics.

Methods
This study enrolled 270 patients with ESRD receiving HD at a medical center in southern Taiwan in 2021.Patients' demographic and clinical characteristics were collected by reviewing medical charts. The self-reported localized and systemic AEs were collected via a face-to-face survey on the 2nd- and 7th- day after the first dose of ChAdOx1 nCoV19 vaccination. The variables recording AEs status were dichotomized, representing with or without the symptoms. Personal identification number were deleted in this dataset.